WO2014138723A2 - Boisson d'optimisation physique - Google Patents

Boisson d'optimisation physique Download PDF

Info

Publication number
WO2014138723A2
WO2014138723A2 PCT/US2014/022204 US2014022204W WO2014138723A2 WO 2014138723 A2 WO2014138723 A2 WO 2014138723A2 US 2014022204 W US2014022204 W US 2014022204W WO 2014138723 A2 WO2014138723 A2 WO 2014138723A2
Authority
WO
WIPO (PCT)
Prior art keywords
solution
sodium
calcium
composition
alkal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/022204
Other languages
English (en)
Other versions
WO2014138723A3 (fr
Inventor
Suzannah Jane ROBERTS
Stephanie Jo BLACKWELL
Shannon Joe BROWN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognate3 LLC
Original Assignee
Cognate3 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognate3 LLC filed Critical Cognate3 LLC
Publication of WO2014138723A2 publication Critical patent/WO2014138723A2/fr
Publication of WO2014138723A3 publication Critical patent/WO2014138723A3/fr
Anticipated expiration legal-status Critical
Priority to US16/881,880 priority Critical patent/US20200281968A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides

Definitions

  • Th is appl ication claims priority benefit of United States Provisional patent appl ication Serial No. 6 1 /774,622, filed March 8, 20 1 3 and United States Provisional patent appl ication Serial No. 61 /774,626, H ied March 8, 20 1 3, the d isclosure of each which is incorporated herein in its entirety by reference.
  • the present invention relates to methods of mak ing a non-corrosive base sol ution and the use of the non-corrosive base solution to alter physiological pl l in mammal ian subjects. More spcci tical ly, the present invention relates to methods and compositions for optimizing health and performance; preventing illness: decreasing recovery times from exertion, illness, and inj ury; increasing energy levels; improving exercise performance; improving hydration; preventing muscle damage after exercise; and increasing stamina during exercise.
  • the normal pH of the muscle cel l is 7. 1 but if the bui ldup of H+ continues and pl l is reduced to around 6.5 then muscle contraction may be impaired.
  • Respiratory acidosis may be caused by chronic obstructive pu lmonary disease, asthma, respiratory depressants or sleep apnea.
  • Metabolic acidosis may be caused by ethanol, diabetic ketoacidosis, urem ia, sepsis, shoc k, methanol/ethylene glycol, sal icylate overdose, diarrhea and carbonic anhy drase inh ibitors.
  • the human body attempts to maintain optimal pi I through the actions of buffers. respiration, and renal function.
  • buffers such as proteins, phosphate and l ICOr act to control the pl l level.
  • Respiration maintains a constant carbon ic acid level at 1 .2meq/l or PaC0 2 of 40 mmHG through either excretion or retention of C0 2 by the lungs. Respiration can also rapidly compensate for changes in pi I by altering the level of PaC 2 through the alteration of alveolar ventilation.
  • the renal system can also rapidly compensate for changes in pi I by altering the level of PaC 2 through the alteration of alveolar ventilation.
  • compositions that can compensate for the failure of regulatory mechanism s to maintain physiological pH and prevent acidosis regardless of the cause of the acidosis.
  • compositions that can compensate for the fai lure of regulatory mechanisms to maintain physiological pH despite continued insult to an ind ividual ' s system.
  • compositions and methods for maintaining optimal physiological pi I and treating or preventing ac idosis in physiological fluids or compartments of the mammalian body, incl uding in humans may further be used in the treatment of conditions caused or exacerbated by acidosis, including for example lacti c acidosis.
  • Acidosis may be accompanied by the bui ldup of lactate, particularly D-lactate.
  • This buildup of lactate general ly occurs when cel ls are hypoxic and functioning anaerobical ly whether due to i llness and disease or intense exerc ise. Impaired cellular respiration leads to lower pH levels and can be indicative of tissue hypoxia, hypoperfusion, and possible damage.
  • Compositions and methods of the present invention increase pH levels, preventing or treating lactic acidosis (lactate levels>5mmol/L and serum pH ⁇ 7.35).
  • compositions and methods as described herein may treat or prevent acidosis by a variety of means.
  • the compositions and methods of the present invention may decrease lactate levels, specifically D-lactate.
  • the normal blood lactate concentration is 0.5- 1 .0 minol/L.
  • Ind ividuals in various disease states may have lactate concentrations of less than 2 mmol/L.
  • Hyperlactemia is defined as a m i ld-to-moderate persistent increasing blood lactate concentration (2-
  • compositions and method of the present invention may increase the physiological alkalinity of a mammalian subject; bring pH levels to within normal ranges such as between 7.35 and 7.45 for blood and 4.6 and 8 for urine.
  • the normal pH of intracellular and interstitial fluids is maintained because acids are removed at the same rate they are added. If acid is added faster than it is removed, the pH of intracellular and interstitial fluids decreases, resulting in ac idosis.
  • Whi le strong m ineral bases have often been used to neutral ize ac ids, they are very corrosive and are not generally suitable for altering pH in living organisms.
  • the present invention provides compositions and methods for altering base solutions so that they may be effectively used to increase pl l levels in l iving organisms.
  • a base solution with a h igh concentration of OH " ions which may be used as an alkal in ity increasing agent or as an antioxidant.
  • Such a base solution or alkaline water may be formed by any means that generates a solution with a h igh concentrat ion of OH " ions, speci fically an oxide or hydroxide combined with puri fied, disti l led, spring, A ltered, or m ineral-free water.
  • the alkal ine water described herein may be used for a variety of purposes including preventing and treating i l lness, optim izing health and performance, decreasing recovery times from exertion, and increasing stam ina during exercise.
  • a lkal ine water may be manufactured by whatever means usefu l to create a water with a pl l between about 7 to about 14, preferably a pH of about 7.5 to about 1 2.75, preferably a pH of about 10 to about I 1 , about 1 2 to about 14, about 1 2.25 to about 12.75. more preferably about 1 2.3 to about 1 3.8, preferably a pl l of about 1 2.5 to about 1 3.75.
  • alkal ine water may be manufactured by combining oxides inc luding, but not l imited to, calcium hydroxide, calcium oxide, sodium hydroxide, sod ium oxide, potassium hydroxide, potassium oxide, magnesium hydroxide, or magnesium oxide, with mineral free water to create a non-corrosive base solution with a high concentration of OH- ions.
  • the solution containing the oxide or hydroxide and water is sti rred to increase a rate or amount of dissociation of the OH " ions.
  • the ionic concentration in the water wi l l result in a conductivity measurement of between about 5( S/cm to about 2000 ⁇ 8/ ⁇ , preferably between about I OC ⁇ S/cm to about ⁇ 000 ⁇ 5/ ⁇ , preferably about 500 ⁇ 8/ ⁇ to about 800 ⁇ 8 ⁇ : ⁇ , preferably about 650 ⁇ 8/ ⁇ to about 750 ⁇ 8/ ⁇ , preferably about 700 ⁇ / ⁇ to about 2000 ⁇ / ⁇ . preferably about 700 ⁇ / ⁇ to about 750 ⁇ / ⁇ .
  • the resulting concentrated alkaline water may be consumed d irectly or di luted with filtered water to a pH of about 7 to about 1 0, about 7.5 to about 8.
  • the di luted alkaline water will have a conductivity of about 45 ⁇ / ⁇ to about
  • 90 ⁇ 8/ ⁇ , i n some embod iments about 50 ⁇ / ⁇ to about 75 ⁇ / ⁇ , and in certain embodiments about 50 to about 60 ⁇ / ⁇ .
  • the alkal ine water may be made with calcium hydroxide.
  • Calcium hydroxide (Ca(01 -1) 2 ) is a base which wil l only dissoc iate sl ightly in a weak acid environment. At a pH of 5.5 or higher, calcium hydroxide rapid ly loses its solubi lity and at a pH of 8.0 it is insoluble.
  • a method is provided herein of increasing the solubi l ity of calcium hydroxide al lowing a larger volume of Ca(OH) 2 to be dissociated in solution including weakly acid ic, neutral or sl ightly basic solutions.
  • a means of raising the pi I of a Ca(OH)i solution at least one pi I point higher than a normal saturated calcium hydroxide solution is provided .
  • a method of increasing the reactivity o f Ca(OH) 2 in solution is provided.
  • Usefu l forms of calcium hydroxide for use with in the formulations and methods of the invention inc lude the forms described herein, as wel l as solvates, hydrates, or combinations thereof.
  • Su lfuric ac id is a strong mineral acid.
  • sulfuric acid in water is treated to reduce the acid ity whi le maintain ing the concentration of sulfate in the solution.
  • Such treatment may be accomplished by any means possible, incl uding the addition of oxygen to the sul furic acid solution.
  • the su lfuric acid solution is in fused with ozone.
  • Such treatments may increase the pH of the sulfuric acid solution, creating a neutral or basic solution which may then be combined with the calcium hydroxide solution described above to create a non-corrosive base solution with a h igh concentration of OH " ions.
  • calc ium oxide (CaO), another strong base, is used as the acid neutral izing agent and/or antioxidant.
  • Calcium oxide is stirred into puri fied, disti l led or mineral free water to create a non-corrosive base solution with a h igh concentration of OH ' ions.
  • Such a solution wil l have a pH between about 7 to about 1 4, preferably a pH of about 12 to about 14, more preferably about 1 2.3 to about 13.8. preferably a pH of about 12.5 to about 13.75 and an ionic
  • the concentration such that the conductivity would be about 50 ⁇ 8/ ⁇ to about 200( ⁇ S/cm. preferably between about ⁇ ⁇ / ⁇ to about l OOC ⁇ S/cm, preferably about 500 ⁇ / ⁇ to about 800 ⁇ / ⁇ , preferably about 650 S/cm to about 750 ⁇ 8/ ⁇ . preferably about 700 ⁇ : ⁇ to about 750 ⁇ / ⁇ .
  • the ionic concentration is such that the conductivity may be between about 700 ⁇ / ⁇ to about 200(tyS/cm.
  • the resulting concentrated alkaline water may be consumed directly or diluted with filtered water to a pH of about 7 to about 10, about 7.5 to about 8.
  • the diluted alkaline water may have a conductivity of about 45 ⁇ / ⁇ to about
  • compositions and methods described herein employ a base solution (also referred to as an OH " solution or alkaline water) as described above to increase or maintain physiological pH in a mammalian subject.
  • a base solution also referred to as an OH " solution or alkaline water
  • Alkaline water as described herein may be used to increase physiological pi I in a mammalian subject for a variety of reasons including to speed recovery times, particularly from periods of stress or intense physical activity: to increase endurance; to increase physical performance; to optimize health and performance: and to prevent illness.
  • Alkaline water as described herein may additionally be used to treat symptoms of acidosis in mammalian subjects.
  • symptoms include, but are not limited to, extreme tenderness in the joint, inflammation, swelling, pain, redness in the affected area, confusion, lethargy, rapid breathing, shortness of breath, wheezing, chest pain or pressure, joint stiffness, swelling, joint deformity, crepitus, non- specific fever, joint inflammation, headaches, fatigue, constipation, a feeling of euphoria, nausea, seizures, coma, generalized weakness, abnormal heart function, decreased platelet count, areas of mottled skin, fever, low blood pressure, tachycardia, skin discoloration, irregular heartbeat, loss of appetite, jaundice, abdominal pain, easy bruising, vomiting, ascites, dry skin, dry mouth, low blood pressure, frequent urination, chest pain, lymph node pain, night sweats, skin rash, hyperventilation, abdominal pain, severe anemia, muscoskeletal pain, memory issues, and light headed
  • Alkaline water as described herein may additionally be used to treat mammal ian subjects with acidosis, as well as conditions associated with or complicated by acidosis including, but not limited to, methicillin resistant staphylococcus aureus (MRSA), sepsis, folliculitis, gout, arthritis, hypoxia, hypoperfusion, hemorrhage, ethanol toxicity, shock, hepatic disease, diabetic ketoacidosis, exercise fatigue, non-Hodgkin ' s and Burkitt ' s lymphoma, hyperventilation, abdominal pain, lethargy, shock, severe anemia, hypotension, irregular heart rhythm, tachycardia, fibromyalgia, weight gain, cancer, cardiovascular disease, respiratory disease, infection, diabetes, cellulitis and pancreatic impairment.
  • the compositions and methods of the present invention are used as anti-bacterial agents.
  • alkaline water may be taken in a concentrated formulation with a pH of between about 12 to about 13.75, preferably about 12 to about 12.5 and a conductivity of about 700nS/cm to about 200C ⁇ S/cm, preferably about
  • Alkaline water as described herein may be diluted with water to a pH of about 6.9 to about 7.5, in some embodiments about 6.9 to about 7.2, and in other embodiments about 7.0, with a conductivity 45 ⁇ 8/ ⁇ to about 60 ⁇ 8/ ⁇ . and in some embodiments about 50 ⁇ 8/ ⁇ to about 55 ⁇ 8/ ⁇ .
  • Any type of water that will lower the pi I may be used for the dilution including, but not limited to, tap, spring, distilled, reverse osmosis, mineral-free or filtered water.
  • Alkaline water may be taken alone, or in a coordinate or combined formulation with one or more additional agents to optimize health and performance; prevent illness; decrease recovery times from exertion, illness and injury; and extend endurance during exercise.
  • Useful secondary or additional agents for use within the formulations and methods of the present invention include, but are not limited to, alkalinity increasing agents, adaptogens, amino acids and amino acid derivatives, anti-inflammatory agents, anti-nausea agents, analgesics, antioxidants, aphrodisiacs, detoxifying agents, dietary supplements, herbal supplements, calming agents, herbs and plant extracts, essential nutrients, coenzymes, electrolytes, energy boosters, essential trace elements, flavonoids, hormones, immune boosters, neurotransmitters. essential fatty acids, memory enhancers, vitamins and m inerals, protein, sedatives, stimulants and nutritional supplements for use within the formulations and methods described herein.
  • compositions described herein may additionally contain sweeteners.
  • novel methods and compositions for maintaining optimal pi 1 in mammal ian subjects and treating or preventing acidosis, symptoms of acidosis, and conditions caused by or exacerbated by acidosis are effective for optimizing health and performance; preventing illness; decreasing recovery times from exertion, il l ness, and inj ury; increasing energy levels; improving exercise performance; improving hydration; preventing muscle damage after exerc ise; and increasing stam ina during exercise.
  • Formu lations and methods described herein provide a non-corrosive strong base solution (a lso re ferred to as an Oi l " solution, a base solution, or alkal ine water) and methods for using the solution for the regulation of physiological pH in vertebrates, including mammals.
  • a non-corrosive strong base solution a lso re ferred to as an Oi l " solution, a base solution, or alkal ine water
  • the formu lations described herein may be manufactured and sold in a variety o f forms. In some embodiments, they may be manufactured and sold as a single strength beverage for direct consumption by the consumer. In other embodiments, the formulations may be sold in an aqueous concentrate to be diluted with water to yield a beverage that treats or prevents acidosis, sym ptoms of acidosis, and conditions caused by or exacerbated by acidosis.
  • the formulations may also be sold as a powder, granule formation, or tablet wh ich is to be d issolved i n water to yield a beverage that treats or prevents acidosis, sym toms of ac idosis, and conditions caused or exacerbated by acidosis.
  • Mammalian subjects amenable for treatment according to the formulations and methods of the invention further include, but are not l imited to, human and other mammal ian subjects at risk for or with symptoms of acidosis, as well as symptoms or conditions associated with or compl icated by acidosis.
  • Acidosis may be caused by any of a variety of reasons including, but not l im ited to, intense exercise, i llness, stress, diet, exposure to toxins, and poor sleeping habits.
  • compositions and methods described herein are usefu l for optim izing health and performance; preventing illness; decreasing recovery times from exertion, i l lness, and inj ury; increasing energy levels; improving exercise performance; improv ing hydration; preventing muscle damage after exerc ise; and increasing stam ina during exercise. They are additionally useful for treating, preventing or al leviating symptoms of acidosis, including, but not l imited to, extreme tenderness i n the joint, inflammation, swell ing, pai n, redness in the affected area, con fus ion, lethargy, rapid breathing, shortness of breath, wheezing, chest pain or pressure. joint stiffness, swel ling, joint deform ity, crepitus, non-spec i fic fever, joint inflammation, headaches, fatigue, a feeling of euphoria
  • the formulations and methods described herein are additionally useful in the treatment of mammal ian subjects with acidosis, as well as conditions associated with or compl icated by acidosis including gout, abdominal pain, A lzheimer ' s disease, amyotrophic lateral sc lerosis, fungal in fections includ ing but not limited to candid iasis, arthritis, atherosclerosis, cancer, cardiovascular disease, cataracts, cellul itis and pancreatic impairment, chronic obstructive pulmonary disease, coronary artery disease, d iabetes, diabetic ketoacidosis, ethanol toxicity, exerc ise fatigue, fol liculitis, gout, heart failure, hemochromatosis, hemorrhage, hepatic disease, hepatitis C, hypertension, hyperventilation, hypotension, hypoxia and hypoperfusion, infection, inflammatory bowel disease, irregular heart rhythm.
  • Lesch-Nyhan syndrome lethargy, macular degeneration, methicil l in resistant staphylococcus aureus (MRSA), Morgellons disease, fibromyalgia, multiple sclerosis, nausea, non-Hodgkin's and Burkitt ' s lymphoma, Parkinson ' s disease, psoriasis, regional hypoperfusion, pancreatic impairment, reperfusion injury, respiratory disease, Reynaud ' s phenomenon, sepsis, severe anem ia, shock, tachycardia, tinea cruris, tinea pedis, candidiasis, vom iting and weight gain.
  • MRSA methicil l in resistant staphylococcus aureus
  • a further embodiment of the present invention provides a strong base solution (also referred to as an 01 1 " solution, a base solution or alkal ine water) for use in the prevention of secondary infections in vertebrates, includ ing mammal ian subjects; particularly mammal ian subjects with comprom ised immune system s, such as those subjects suffering from chron ic diseases such as, but not l im ited to, cancer or I I I V, or whose immune systems are comprom ised due to treatments for diseases such as cancer.
  • a strong base solution also referred to as an 01 1 " solution, a base solution or alkal ine water
  • Antioxidants may be used in the reduction of reactive oxygen species in vertebrates, including mammals.
  • Reduction of free radicals and other reactive oxygen species (ROS) is effective in the treatment of diseases includi ng, but not l imited to, gout, abdominal pain, Alzheimer ' s disease, amyotrophic lateral sclerosis, arthritis, atherosclerosis, cancer, cardiovascular disease, cataracts, cel lu l itis and pancreatic impairment, chronic obstructive pulmonary d isease, coronary artery disease, diabetes, diabetic ketoacidosis, ethanol toxicity, exercise fatigue, fol licul itis, gout, heart fai lure, hemochromatosis, hemorrhage, hepatic disease, hepatitis C, hypertension, hyperventi lation, hypotension, hypoxia, hypoperfusion, infection, inflammatory bowel disease, irregul ar heart rhythm.
  • ROS reactive oxygen species
  • Lesch-Nyhan syndrome lethargy, macular degeneration, methicil lin resistant staphylococcus aureus (MRSA), fibromyalgia, multiple sclerosis, nausea, non- Hodgkin's and Burkitt's lymphoma, Parkinson ' s disease, psoriasis, regional hypoperfusion, pancreatic impairment, reperfusion inj ury, respiratory disease, Reynaud's phenomenon, sepsis, severe anem ia, shock, tachycardia, vom iting and weight gain.
  • Formulations and methods herein may additional ly employ a base solution as an antioxidant or free radical scavenger for the regulation of ROS levels including free radical levels.
  • the calcium hydroxide or calcium oxide or other oxides and hydroxides used to produce the OH " solution may be provided in any of a variety of forms, incl uding solvates, hydrates, or combinations thereof.
  • Formulations contain ing a non-corrosive strong base solution made from calcium hydroxide or calcium oxide or other hydroxide or oxide as disclosed herein are effectively used to treat mammal ian subjects suffering from an over accumulation of free rad icals as wel l as diseases and conditions assoc iated with free rad icals.
  • the fol low ing terms and de divisions are provided by way of example. Additional terms and definitions for describing embod iments of the present invention are provided by way of example elsewhere in the application.
  • microbial refers to any m icroorgan ism capable of causing disease. Such microorgan isms include fungal, viral and bacterial m icroorgan isms.
  • effective amount of a compound is meant a non-toxic but suffic ient amount of the compound to provide the desired function, i.e., anti-infective, as an antioxidant, or acid-neutralizing agent. An appropriate effective amount may be determ ined by one of ordinary ski ll in the art using on ly routine experimentation.
  • Formu lations and methods herein employ alkaline water or an OH " solution alone or w ith one or more additional agents to optimize health and performance; prevent i l lness; decrease recovery times from exertion, i l lness and inj ury ; and extend endurance during exercise.
  • Useful secondary or additional agents for use with i n the formulations and methods of the present invention include, but are not l im i ted to, alkal in ity increasing agents, adaptogens, am ino acids and amino acid derivatives, anti-inflammatory agents, anti-nausea agent s, analgesics, antioxidants, aphrodisiacs, detoxifying agents, dietary supplements, herbal supplements, calm ing agents, herbs and plant extracts, flavorings, essential nutrients, coenzymes, electrolytes, energy boosters, essential trace elements, flavonoids, hormones, immune boosters, neurotransmitters, essential fatty acids, memory enhancers, vitamins and minerals, protein, sedatives, sti mulants and nutritional supplements for use within the formulations and methods described herein.
  • the secondary agent may be provided in any of a variety of forms, including any polymorphs, enantio ners,
  • compositions and secondary agent may be administered either combinatorially or coordinately as disclosed herein to effectively optimize health and performance; prevent i l lness; decrease recovery times from exertion, il lness, and inj ury; increase energy levels; improve exercise performance; improve hydration; prevent muscle damage after exercise; and i ncrease stam ina during exercise.
  • a lkal inity increasing agents for use within the formulations and methods of the present invention include, but are not l im ited to sodium bicarbonate; a carbonate, a phosphate, or a hydroxide of sodium or potassium ; magnesium carbonate;
  • magnesium hydrox ide ammonium carbonate; ammonium bicarbonate;
  • magnesium oxide sodium or potassium citrate, bicarbonate, sul fate, and bcnzoate; ascorbate; calc ium carbonate; any pharmaceutical ly acceptable material that causes the pl l of an aqueous medium to rise above pl l 7.0, or m ixtures thereof.
  • Formulations and methods as described herein may include adaptogens.
  • An adaptogen is a metabol ic regulator which increases the abi l ity of an organ ism to adapt to environmental factors, and prevents damage from such factors.
  • Exemplary adaptogens include, but are not l imited to, ashwagandha.
  • Antioxidants incl uded in the formulations provided herein may be in the form of nutritional supplements such as, but not l imited to, vitam in A. vitam in C, vitam i n I:, erythorbic ac id, beta-carotene, carotenes, lutein, manganese, lycopene.
  • Plant extracts containing antioxidants may come from plant sources such as, but not l imited to, apricot, acai fruit, acerola, apple, blueberry, blackberry, black currant, carrots, cherry, chokeberry, cranberry, elderberry, green tea, goj i berry, grape seed, mangosteen, maqui berry.
  • Formulations and methods herein may further employ vitamin, mineral and nutritional supplements in a variety of forms including, but not l im ited to, vitam in B complex, folic acid, niacin, niacinamide, pantothenic ac id, pyridoxine HC1 .
  • vitam in B2 folate, biotin, vitamin C, vitamin D, vitamin D3, vitamin E, vitam i n , cyanocobalam in, inositol, thiamine, thiam ine mononitrate, calcium
  • pantothenate m ixed tocophyerols, d-alpha tocopheryl acetate, magnesium, calcium, calcium carbonate, calcium chelate, calcium di-phosphate, calcium phosphate, iron, magnesium carbonate, magnesium citrate, magnesium oxide, magnesium phosphate, manganese chelate, manganese sulfate, potassium, potassium chelate, potassium chloride, sodium, zinc, vanadyl sulphate, chromi um, chrom ium chloride, chromium picolinate, and chrom ium polyn icotinate.
  • the amount of vitam in, mineral and nutritional supplements may vary in the formulations and methods described herein.
  • the formu lat ions may comprise independently between about 1 % and to about 250% of the U .S. recom mended dai ly al lowance, about 1 0% to about 250%, about 1 0% and 1 50%, between about 10% to about 1 00%, about 1 0% to about 50% of the U .S. recommended dai ly al lowance of any one vitam in, m ineral or nutritional supplement.
  • the composition as described herein has between 1 0% to 250%, about 1 0% to about 1 50%, about 25% to about 1 00%, about 50% to about 75% of the U .S. recommended daily amount of vitamin B or vitam in B complex.
  • compositions and methods described herein may further include am ino acids, am ino acid precursors, and amino acid derivatives whether branched or straight chain amino acids.
  • am ino acids, precursors and derivatives which may be used in the formulations and methods described herein inc lude, but are not l imited to, 5-HTP, argin ine, beta alanine, carn itine fumarate, citrulline malate, glutam ine peptide, glycine, l-alanine, 1- argin ine, l-arginine hydrochloride, 1-histid ine, 1-methionine, 1-lysine HC l, 1- phenylalan ine, leucine ethyl ester, l-glutam ine, 1-isoleuc ine, 1-thean ine, l-tyrosine, phenylalan ine, taurine, tri-methyl glycine, tryptophan, tyrosine,
  • Electrolytes used herein include, but are not limited to, sodium chloride, sodium acetate, acidic sodium citrate, acidic sodium phosphate, sodium chloride, sod i um bicarbonate, sodium bromide, sodium citrate, sodium lactate, sodium molybdate.
  • sodium phosphate anhydrous sodium sulphate, sodium sulphate, sodium tartrate, sodium benzoate, sodium selenite, and other sodium salts and mixtures thereof: potassium chloride, potassium acetate, potassium bicarbonate, potassium brom ide, potassium citrate. potassium-D-gluconate, monobasic potassium phosphate, potassium tartrate, potassium sorbate, potassium iodide, and other potassium salts and mixtures thereof; magnesium carbonate, magnesium citrate, magnesium oxide, magnesium phosphate, as well as other magnesium salts and m ixtures thereof; calcium chloride, calcium carbonate, calcium chelate, calcium d i- phosphate, calcium lactate, calcium phosphate tribasic and other calcium salts and m ixtures thereof.
  • Such electrolytes may be included in the formulations described herein in proportions and amounts suitable to replenish salts lost during exercise or i l lness or otherwise depleted.
  • Additional agents wh ich may be used in the compositions and methods descri bed herein incl ude anti-inflammatory agents including, but not l im ited to, extracts from plants such as maqui berry, milk thistle, sku l l cap, red raspberry, red sour cherry, green tea and hops.
  • agents which may be used in the compositions and methods described herein incl ude anti-nausea agents including, but not lim ited to, extracts from pepperm int, ginger and chamom ile.
  • compositions and methods described herein incl udes analgesic agents such as, but not l im ited to, wh ite wi llow bark.
  • the formu lations and methods described herein may add itional ly include herbal supplements and extracts with beneficial properties including, but not l imited to, passion flower, horny goat weed, skullcap, m i lk thistle. Ech inacea, dandel ion l af
  • the formu lations and methods described herei n may further include plants with beneficial properties including, but not l imited to, guarana seeds, acerola berries.
  • Mammalian subjects suffering from acidosis may be exercising intensely.
  • compositions and methods described herein may further include energy boosters that may increase performance including, but not limited to, creatine ethyl ester, creatine monohydrate, magnesium creatine chelate, creatine hydrochloride, creatine nitrate, creatine monohydrate and royal jelly.
  • Flavonoids are plant pigments present in a wide range of fruits, vegetables, and nuts. In humans, they may have anti-inflammatory, anti-cancer and anti-viral properties. Useful flavonoids within the compositions and methods of the present invention are present in chamomile extract, cocoa powder, red grape, black tea, and white tea, ginkgo biloba, berries, parsley, and green tea some or all of which may be included in the compositions and methods described herein.
  • the Alkaline water compositions described herein may additionally include sedatives to encourage relaxation or to make those suffering from illness and disease more comfortable.
  • sedatives include, but are not limited to, including, but not limited to, lavender, lemon balm, lemongrass, linden, oatstraw.
  • formulations and methods described herein may further include stimulants.
  • Such stimulants include, but are not limited to, caffeine, citicoline, d- glucuronolactone, guarana extract, ginseng, concentrated green tea, green coffee beans, glucuronolactone, guarana, panax ginseng, panax quinquefolius, Siberian ginseng, and theobromine.
  • immune boosters including, but not limited to, Fxhinacea and astragalus root.
  • compositions herein may additionally comprise one or more flavoring agents.
  • flavorings are any flavoring typically included in a beverage composition including, but not limited to synthetic flavorings, fruit juice, vegetable juice, milk solids, fruit flavors, herbal flavor and mixtures thereof.
  • the fruit juice can be any citrusjuice, non-citrusjuice, or mixture thereof, which is known for use in dilute juice beverages.
  • the juice can be extracted from, but not limited to, apple, cranberry, pear, peach, plum, apricot, nectarine, grape, guava. cherry, currant.
  • the vegetable juice can be any vegetable j uice general ly consumed including, but not limited to, celery, spinach, cabbage, watercress, carrot, beet, spira l ina, sweet potato, kale, romaine, col lard greens, endive, escarole, bok choy, fennel, parsley, wheat grass, or cucumber.
  • Such fruit and vegetable j u ices may or may not have additional beneficial properties such as antioxidants and/or flavonoids.
  • Formulations and methods herein may additionally include a protein source.
  • Protein sources include, but are not lim ited to, mi lk solids, calc ium caseinate, whey protein concentrate, whey protein isolate, whey protein hydrolysate, soy protein, casein hydrolysate, rice protein, wheat protein, corn protein, partial ly hydro lyzed whey protein, or ultra-filtered whey protein.
  • Formu lations and methods herein may further incl ude one or more sweeteners or carbohydrate source.
  • Sweeteners which may be used in the formulations herein include, but are not limited to, acesullame potassium, aspartame, cane sugar, beet sugar, corn syrup, crystal l ine fructose, dextrose, D-ribose, fructose, glucose, glucose-fructose syrup, high fructose corn syrup, high fructose l iquid sugar, honey, maltodcxtrin.
  • sorbitol stevia, sucralose, sucrose, sugar, trehalose, truv ia or xyl itol .
  • compositions and methods described herein are particularly useful for optim izing health and performance; preventing i l lness; decreasing recovery times from exertion, i l lness, and inj ury; increasing energy levels; improving exercise performance; improving hydration; preventing muscle damage after exerc ise; and increasing stam ina during exercise.
  • the formulations described herein may be used prophy lactical ly or therapeutically.
  • the formulations described herein may be administered to a mammal ian subject prior to or duri ng strenuous exercise in order to prevent or reduce acidosis or symptoms or sequelae of acidosis.
  • the formulations described herein may be used to treat mammalian subjects with acidosis or symptoms of acidosis including, but not limited to, extreme tenderness in the joint, inflammation, swel ling, pain, redness in the affected area, confusion, lethargy, rapid breathing, shortness of breath, wheezing, chest pain or pressure, joint sti ffness, swel l ing, joint deformity, crepitus, non-speci fic fever, joint inflammation, headaches, fatigue, a feeling of euphoria and nausea, seizures, coma, generalized weakness, abnormal heart function, decreased platelet count, areas of mottled skin, fever, low blood pressure, tachycardia, skin d iscoloration, irregular heartbeat, loss of appetite,
  • the formulations described herein may be used to treat human and other mammalian subjects with acidosis and/or excessive free rad ical production as wel l as those su ffering from conditions or compl ications of hav ing acidosis including increased susceptibi l ity to m icrobial infections or other secondary infections; skin infections such as, but not lim ited to, psoriasis, Morgel lons disease, and fungal infections such as candidiasis, tinea cruris, and tinea pedis; cancer; d iabetes; cel lulitis; or pancreatic impairment; and/or mammals in need of antioxidant treatment or free radical el im ination, incl uding those su ffering from cond itions or complications assoc iated with excess free radicals, including, but not lim ited to, gout, Lesch-Nyhan syndrome, hemochromatosis, A lzheimer ' s disease, am
  • Alkaline water, or water with a high concentration of OH- ions may be manufactured by any means generally used.
  • alkaline water may be manufactured by combining oxides and hydroxides including, but not limited to. calcium hydroxide, calcium oxide, sodium hydroxide, sodium oxide.
  • potassium hydroxide, potassium oxide, magnesium hydroxide, or magnesium oxide w ith water to create a non-corrosive base solution with a high concentration of OH- ions.
  • the water may be tap, spring, mineral-free, filtered, purified, distilled, or any other suitable water with a low mineral concentration.
  • the OH " solution ofthe present invention may be formed through the dissolution of calcium hydroxide in water.
  • the calcium may be between 2 and 10% mole weight, preferably between 2 and 6% mole weight, more preferably 4% mole weight in water. Dissociation ofthe calcium hydroxide in water may be facilitated by any means applicable.
  • the calcium hydroxide solution may be agitated. In other embodiments, the calcium hydroxide solution may be exposed to a magnetic Held.
  • the calcium hydroxide solution may be agitated while being exposed to a magnetic field.
  • substantial dissolution is such that the dissociation ofthe calcium hydroxide is increased to betw een 50 and 95% of maximum dissociation, preferably between 50 and 75% of maximum dissociation, more preferably between 75 and 95% of maximum dissociation, in some cases greater than 95% dissociation.
  • maximum dissociation is meant that when additional calcium hydroxide is added to the solution at a given temperature or pressure, the calcium hydroxide precipitates out regardless ofthe length of time or additional agitation.
  • agitation ofthe calcium hydroxide solution in a magnetic field increases the pH of the calcium hydroxide solution to at least one pH unit higher than a normal saturated Ca(OH) 2 solution, in some embodiments even 1 to 3 pH units higher than a normal saturated Ca(OH) 2 solution.
  • agitating the solution in a strong magnetic field increases the solubility ofthe Ca(OH) 2 to greater than normal, preferably 2-200 times greater than normal, more preferably 50 to 100 times greater than normal, preferably 100 times greater than normal.
  • the magnetic field to which the calcium hydroxide solution is exposed may be generated by any means appl icable. In some em bodiments, the magnetic field may be generated by magnets, magnetic water treatment units or other magnet ic field generating apparatus.
  • Such magnetic field generating apparatus may be composed of one or a plural ity of magnets w h ich may surround, be placed around, or be otherwise disposed of adjacent to the container containing the Ca(OH)2 solution. Any kind of magnet or apparatus that creates a strong magnetic field may be used. Magnets which may be used as part of magnetic water treatment units or to otherwise generate a magnetic field include, but are not lim ited to. NdFcB (Neodym ium-lron-Boron), Ferrite, A IN iCo (A lum inum-N ickel-Coba't),
  • SmCo (Samari um Cobalt), A lcomax (alloy of iron, nickel, alum inium, cobalt a nd copper). Cunife (copper, nickel and iron or copper, nickel, iron and cobalt ), and fernico (iron, n ickel, cobalt) magnets.
  • the magnets may be monopolar or bipolar. I n other embod iments, the magnetic field generating apparatus may comprise electromagnets. In additional embodiments, the magnets may be encased in a housing.
  • Such a housing may be made of any material appl icable, including, but not lim ited to, metals such as, but not lim ited to, alum inum, or steel ; and plasti cs, or any combination thereof.
  • magnets on opposing sides of the container holding the solution may have opposite poles, such that, for example, the positive and negative poles face each other.
  • the magnet s may rotate around the container of calcium hydroxide solution.
  • I n in order to increase the 01 f concentration of a calc ium hydroxide sol ution, it may be combined with a solution made from sul furic aci d.
  • I n order to create the solution made from sulfuric acid, su lfuric acid is added to water.
  • enough sul furic acid is added to water to create a solution of equal molar strength to the Ca(OH ) 2 in the calcium hydroxide sol ution.
  • the concentration of the solution will be about 0.02% to about 0.08 % ac id in water by volume, preferably about 0.04% to about 0.06% acid in water by volume.
  • the concentration may be about 50- 1 00 ml of sulfuric acid (Baume 12°) per gallon of water, preferably about 70 to about 80 ml, more preferably about 70 to about 78 ml of sulfuric acid per gall on of water.
  • the sulfuric acid solution may be agitated unti l substantial dissociation occurs such that 75 to 100 % of maximum dissociation is achieved, preferably 75 to 95% of maximum dissociation, more preferably 80 to 95% of maximum dissociation of sulfuric acid, in some instances greater than 95% dissoc iation of sulfuric acid.
  • the acidity of the sulfuric acid sol ution may be desirable to reduce the acidity of the sulfuric acid sol ution.
  • the reduction of acidity may occur through any means appl icable.
  • the reduction of acidity may occur through the introduction of additional oxygen to the solution.
  • nascent oxygen may be introduced into the sulfuric acid solution, in another embodiment, the sulfuric acid sol ution may be treated with ozone by circulating the solution through ozone generators. The ozone generators dissociate an oxygen wh ich is consumed by (2 1 I t ) ion(s) in the acid solution to create water.
  • the acid solution may be rec irculated through the ozone units unti l a particu lar concentration of oxygen i s absorbed or a particular pH is achieved .
  • the sul furic ac id solution wi l l be run through the ozone generators until the pH increases by at least 1 to 6 points, preferably at least 1 to 4 points, more preferably at least 2 to 3 points.
  • the sulfuric acid solution wi l l be circulated through ozone generators unti l the pi 1 reaches or exceeds about 7.0.
  • the neutral ized acid solution may then be slowly added to the calcium hydroxide solution to form a resultant m ixture.
  • the free calcium in the calcium hydroxide solution w il l react with the sulfate ions (SCV ⁇ ) in the acid solution to create insoluble anhydrous calci um sulfate precipitate.
  • the mixture may then be agitated until the reactio n goes to completion and the anhydrous calcium su l fate may be filtered or otherw ise removed from the solution.
  • a non-ion ic surfactant may be added to the resulting mixture in order to enhance precipitation.
  • non-ionic surfactants may include, but are not lim ited to, linear or nonyl-phenol alcoho ls or fatty acids, alcohol ethoxylates, alkylphenol ethoxylates, alkyl polyglycosidcs.
  • alkyl ethers such as polyoxycthylene octyl ether, polyoxyethylene lauryl ether, polyoxyethylene stearyl ether, and polyoxyethylene oleyl ether; alkyl pheny l ethers such as polyoxyethylene octylphenyl ether, and polyoxyethylene nonylphenyl ether; alkyl esters such as polyoxyethylene laurate, polyoxyethylene stearate.
  • alkylamines such as polyoxyethylene laurylamino ether, polyoxyethy lene stearylamino ether, polyoxyethy lene oleylam ino ether, polyoxyethylene soybean amino ether, and polyoxyethylene beef tallow am ino ether
  • alkylamides such as polyoxyethylene lauric amide, polyoxyethylene stearic amide, and polyoxyethylene oleic amide
  • vegetable oil ethers such as polyoxyethylene castor oil ether, and polyoxyethylene rapeseed oil ether
  • alkanolam ides such as lauric acid diethanolamide, stearic acid
  • sorbitan ester ethers such as polyoxyethylene sorbitan monolaurate, polyoxyethy lene sorbitan monopalmilate, polyoxyethylene sorbitan monostearate, and polyoxyethylene sorbitan monooleate.
  • the OH " solution of the present invention may be formed through the dissolution of calcium oxide in water.
  • the calcium may be between 2 and 1 0% mole weight, preferably between 2 and 6% mole weight, more preferably 4% mole weight in water. Dissociation of the calcium oxide in water may be facil itated by any means appl icable. In some embodiments, the calcium oxide solution may be agitated or stirred in order to increase the rate or amount or dissociat ion of the calcium oxide.
  • the solution, however formed may be fi ltered at various stages to remove particulates.
  • the calcium hydroxide solution may be fi ltered prior to combining with the sul furic acid solution and/or the resultant m ixture may be fi ltered to remove particulates.
  • the resu ltant m ixture may be additional ly cooled or partial ly frozen to create a slurry and further puri fied, for example through filtration.
  • the resulting m ixture is cooled to below about 36° F. In another embodiment the resulting m ixture is cooled to below about 36° F but above about 35 ° F.
  • the concentrated OI F solution prepared by combining the calcium hydroxide solution and sulfuric acid solution or dissolution of calcium oxide may be d i luted with water to reach a specified pi I prior to consumption or adm inistration .
  • the water may be non-chlorinated.
  • the water may be spring water.
  • the water may be disti lled.
  • the water may be minera l free water.
  • the water may be generated by an alkaline water machine. I n some embodiments, the resulting mixture may be diluted to a pFI of betw een about 8.0 to about 1 I , more preferably between about 8.5 to about
  • This solution may then be used to effectively neutral ize acids, to treat acidosis, prophylactical ly, to reduce free radicals, and/or as an antioxidant.
  • calcium oxide (CaO) another strong base, is used as I he acid neutralizing agent and/or antioxidant. Calcium oxide is stirred into puri ned, distilled, or m ineral free water to create a non-corrosive base solution with a high concentration of OH " ions.
  • Such a solution wi l l have a pH betw een about 7 to about 14. preferably a pH of about 12 to about 14, more preferably about 12.3 to about 1 3.8, preferably a pH of about 1 2.5 to about 1 3.75 and an ionic
  • concentration such that the conductivity would be about 5( ⁇ S/cm to about 2000 ⁇ / ⁇ , preferably between about ⁇ ⁇ / ⁇ to about ⁇ ⁇ / ⁇ .
  • concentration such that the conductivity would be about 5( ⁇ S/cm to about 2000 ⁇ / ⁇ , preferably between about ⁇ ⁇ / ⁇ to about ⁇ ⁇ / ⁇ .
  • concentration such that the conductivity would be about 5( ⁇ S/cm to about 2000 ⁇ / ⁇ , preferably between about ⁇ ⁇ / ⁇ to about ⁇ ⁇ / ⁇ .
  • the ionic concentration is such that the conductivity is between 7()0 ⁇ / ⁇ to about 2000 ⁇ ; ⁇ .
  • the resulting concentrated alkaline water may be consumed directly or di luted with water to a pH of about 7 to about 10, about 7.5 to about 8.
  • the dil uted alkal ine water may have a conductivity of about 45 ⁇ / ⁇ to about 90 ⁇ / ⁇ , about 50 ⁇ / ⁇ to about 75 ⁇ / ⁇ , about 50 ⁇ / ⁇ to about 60 ⁇ / ⁇ .
  • the water may be non-chlorinated.
  • the water may be spring water.
  • the water may be distil led.
  • the water may be m ineral-free water.
  • the water may be generated by an alkal ine water machine.
  • alkal ine water may be taken in a concentrated formu lat ion with a pH of between about 1 2 to about 1 3.75, preferably about 12 to about 1 2.5 and a conductivity of about 700 ⁇ / ⁇ to about 2000 ⁇ / ⁇ , preferably about 7()0 ⁇ to about 1 500 ⁇ / ⁇ , preferably about 700 ⁇ / ⁇ to about 1000 ⁇ / ⁇ , more preferably about700 ⁇ / ⁇ to about 750 ⁇ / ⁇ .
  • a pH of between about 1 2 to about 1 3.75 preferably about 12 to about 1 2.5
  • a conductivity of about 700 ⁇ / ⁇ to about 2000 ⁇ / ⁇ , preferably about 7()0 ⁇ to about 1 500 ⁇ / ⁇ , preferably about 700 ⁇ / ⁇ to about 1000 ⁇ / ⁇ , more preferably about700 ⁇ / ⁇ to about 750 ⁇ / ⁇ .
  • Alkal ine water as described herein may be diluted with puri fied, disti lled, tap, spring, non-chlorinated, or mineral free water to a pH of about 6.9 to about 7.5, pre ferably about 6.9 to about 7.2, more preferably about 7.0 and a conductivity 45 ⁇ / ⁇ to about 60 ⁇ / ⁇ , preferably about 50 ⁇ / ⁇ to about 55 ⁇ / ⁇ .
  • the acid/alkal inc balance in a healthy mammal is general ly regulated through the actions of buffers, respiration and renal function.
  • Two forms of acid are generated as a result of normal metabolic processes.
  • Oxidative metabol ism produces a large amount of C0 2 dai ly which is excreted through the lungs.
  • the other form of acid results from the metabol ism of dietary protein, resulting in the accumu lation at an average rate of approximately 1 mmol per kilogram of body weight, or 50 to 70 mmol per day of acid in an average adult on a typical western meat containing diet.
  • the most important mechanism preventing change in the pH of extracel lular flu id is the carbon ic acid/bicarbonate buffer system.
  • the importance of th is buffer pair relates to certain key properties: bicarbonate is present in a relatively high concentration in the extracellular fluid (between 24 and 28 mmol/L) and the components of the buffer system are effectively under physiological control : t ie COT by the lungs, and the bicarbonate by the kidneys.
  • ⁇ shift in pH can be brought about by either a primary change in the bicarbonate concentration
  • Respiratory acidosis results from the accumulation of CO2 in the body as a re sult of fai l ure of pulmonary ventilation. This may occur from lesions either in the central nervous system (e.g. depression of cerebral function, spinal cord injury), in the peripheral nervous pathways involved in venti lating the lungs (peripheral nerve and muscle disorders), in some forms of lung disease involving impaired gas d iffusion (e.g. emphysema, asthma, bronchitis, pneumonia, lung cancer or aspiration ), or due to pharmaceutical causes.
  • impaired gas d iffusion e.g. emphysema, asthma, bronchitis, pneumonia, lung cancer or aspiration
  • Metabol ic acidosis may result from inorganic acid addition, i .e. the infusion or i ngestion of 1 IC1 or NI UCl; or through gastrointesti nal base loss through conditions such as diarrhea, small bowel fistula/drainage, surgical d iversion, and renal tubular disorders; stimu lation of chemoreceptors; lactic acid accumulat ion; poison; or diet.
  • the OH " solution of the present invention is effective in the treatment of acidosis regardless of cause.
  • Alkal inity increasing compositions of the invention typically comprise an am ount of a base solution made from calcium hydroxide and/or calcium oxide, its solvates, hydrates, or combinations thereof, wh ich is effective for the treatme nt or prevention of acidosis, as well as complications and related cond itions thereof in a mammalian subject.
  • a lkal ine water may be taken alone, or in a coordinate or combined formulation with one or more additional agents to optim ize health and performance; prevent illness; decrease recovery times from exertion, illness and inj ury; and extend endurance during exercise.
  • Useful secondary or additional agents for use within the formulations and methods of the present invention include, but are not l imited to, alkalinity increasing agents, adaptogens, amino acids and am ino acid derivatives, anti-inflammatory agents, anti-nausea agents, analgesics, antioxidants, aphrodisiacs, detoxifying agents, dietary supplements, herbal supplements, calming agents, herbs and plant extracts, llavorings, essential nutrients, coenzymes, electrolytes, energy boosters, essential trace elements, flavonoids, hormones, immune boosters, neurotransmitters, essential fatty acids, memory enhancers, vitamins and m inerals, protein, sedatives, stimulants and nutritional supplements for use within the formu lations and methods desc ribed herein.
  • the secondary agent may be provided i n any of a variety of forms, including any polymorphs, enantiomers, pharmaceutical ly acceptable salts, solvates, hydrates, or combinations thereof.
  • an alkal inity increasing effective amount of an 01 ⁇ formulation wi l l comprise an amount of the active compound which is therapeutical ly effective by itself or w ith one or more secondary agents, in a single or mu ltiple unit dosage form, taken over a specified period of therapeutic intervention, to measurably al leviate one or more symptoms of acidosis or related conditions in the subject.
  • these compositions are effective within in xivo treatment methods to al leviate acidosis.
  • compositions described herein m ay additional ly contain sweeteners, stabilizers, flavoring, anti-caking agents, flavor protectants, preservatives, anli-foam ing agents, colorants, emulsi fiers and the l ike.
  • Oxidative metabol ism may also cause oxidative stress. Oxidative stress is imposed on cel ls as a result of an increase in oxidant generation (includin g reactive oxygen species), a decrease in antioxidant protection, or a failure to repair oxidative damage.
  • AG s extracel l ular advanced glycation
  • ALEs l ipoxidation end products
  • dysrcg.i lated glucose and l ipid metabol ism are important contributors to oxidant stress, enhanced cel lu lar redox-sensilive transcription factor activity , and impaired i nnate imm une defense, causing inappropriate inflammatory responses mediated in part by reactive oxygen species.
  • Oxygen has two unpaired electrons in separate orbitals in its outer shell.
  • Oxygen-derived radicals are generated constantly as part of normal aerobic life as oxygen is reduced along the electron transport chain in m itochondria. Reactive oxygen species are also formed as necessary
  • radicals derived from penici llam ine, phenylbutazone, some lenamic acids and the aminosal icylate component of sulphasalazinc are currently bel ieved to inactivate protease and deplete ascorbic acid accelerating lipid peroxidation. Free radical production may also be increased by radiation and smoking. Additional ly, inhalation of inorgan ic particles also known as m ineral dust (e.g. asbestos, quartz, and si lica) can, lead to lung inj ury due to free radical production. Fever, excess glucocorticoid therapy and hyperthyroidism also increase the generation of oxygen-derived rad icals due to increased metabol ism.
  • m ineral dust e.g. asbestos, quartz, and si lica
  • antioxidants are substances that when present in low concentrations relative to the oxidizable substrate significantly delays or reduces oxidation of the substrate. Antioxidants protect the body by reacting with free radicals and other reactive oxygen spec ies w ithin the body, hindering ox idation and reducing the amount of c irculating free rad icals. 1 lowever, antioxidant supply is lim ited as an antioxidant molecule c an only react with a single free radical. Therefore, there is a constant need to replenish antioxidant resources, whether endogenously or through
  • compositions and methods of the present invention are effective as antioxidants for the el imination and/or reduction of reactive oxy gen species including free radicals, regardless of the source of the free radicals.
  • Antioxidant compositions of the invention typical ly comprise an amount of a base solution made from calcium hydroxide or calcium oxide, its solvates, hydrates, or combinations thereof by itsel f or with one or more additional agents, which i s effective for the treatment or prevention of excess free radicals as wel l as complications and related conditions thereof in a mammalian subject.
  • an antioxidant effective amount (or free radical reducing effective amount) of an OH " formulation of the present invention will comprise an amount of the acti ve compound by itself or with one or more additional agents which is therapeutical ly e ffective, in a single or multiple unit dosage form, over a speci fied period of therapeutic intervention, to measurably al leviate one or more symptoms of free radical damage or related conditions in the subject.
  • the compositions descri bed herein may additional ly contain sweeteners, stabi l izers, flavoring, anti-caking agents, flavor protectants, preservatives, anti-foaming agents, colorants, emu lsillers and the l ike.
  • amou nt, liming and mode of delivery o f compositions of the invention comprising an effective amount of a base solution either as an alkal inity increasing agent, (antioxidant agent, free radical reducing agent) will be routinely adjusted on an individual basis, depending on such factors as weight, age, gender. and cond ition of the individual, the severity of the acidosis and/or free radical damage or related symptoms, whether the adm inistration is prophylactic or therapeutic, and on the basis of other factors known to effect drug del ivery, absorption, pharmacokinetics, including, but not lim ited to, hal f-li fe, and efficacy.
  • a base solution either as an alkal inity increasing agent, (antioxidant agent, free radical reducing agent)
  • An effective dose or multi-dose treatment regimen for the instant alkalinity increasing or antioxidant formu lations will ordinarily be selected to approxim ate a m.l dosing regimen that is necessary and sufficient to substantially prevent or al leviate acidosis or excess free radical s and related conditions in the subject.
  • ⁇ dosage and adm in istration protocol wi ll often include repeated dosing therapy over a course of several days or even one or more weeks, months, or years.
  • n effective treatment regime may also involve prophylactic dosage adm inistered on a day or mu lti-dose per day basis lasting over the course of days, weeks, months or even years.
  • an “effective amount, " “therapeutic amount,” “therapeutic effective amount. “ or “effective dose” is an amount or dose su fficient to el icit a desired pharmacological or therapeutic effect in a mammal ian subject; typically resulting in a measurable increase in alkalinity or reduction in free radicals.
  • Therapeutic efficacy can alternatively be demonstrated by a measurement of blood gases, electron spin resonance, spin trapping, fingerprinting, measurement o f free radical markers, l iquid chromatography, measurement of markers of oxidative stress, lactic acid measurements, litmus tests, uric acid measurements, or by altering the nature, recurrence, or duration of conditions associated with acidosis and/or excess free radicals.
  • Therapeutic effectiveness may further be demonstrated by a decrease in the symptoms of the conditions being treated, for instance, a decrease in abscesse s, boi ls, redness, pain, headache, a general sick feel ing, muscle aches, shortness of breath, fatigue, fever, shivering and chest pain of m i ld to medium intensity, muscle aches, joint pain, bone pain, chest pain, painfu l breathing, shortness o f breath, fever and chi lls, low blood pressure, fatigue, headaches, rash, malaise.
  • Therapeutic effectiveness may be determined, for example, through an arterial blood gas.
  • arterial blood is taken from any easily accessible artery (typically either radial, brachial or femoral) or out of an arterial l ine. Once the sample is obtained, care should be taken to elim inate visible gas bubbles, as these bubbles can dissolve into the sample and cause inaccurate results.
  • the sealed syringe is then taken to a blood gas monitor. The machine aspirates the blood from the syringe and measures the pH and the partial pressures of oxygen and carbon dioxide and the bicarbonate concentration, as wel l as the oxygen saturation of hemoglobin. Normal pH of blood is between about 7.4 and
  • Effective amounts of the m ixtures of the present invention wil l increase plasma pH from below 7.0 to a pH of about 7.6 to 7.3.
  • Effective alkalinity increasing amounts may increase plasma pH of 6.0 to a pH of about 6.5, preferably to about 6.7, more preferably to about 7.0, preferably to a pH of 7.4 or higher.
  • Therapeut ic effectiveness may also be demonstrated through a litmus test in which a sample of sal iva is taken upon awaken ing and tested with a strip of l itmus paper.
  • a urine sample may also be tested with a strip of l itmus paper or a l itmus test stri p. The l itmus paper is then compared to a l itmus scale to determ ine the pA of the sam ple.
  • the pi I of sal iva is about 7.4 and the pU of urine i s about 6.6.
  • compositions of the present invention are therapeutical ly effective to increase the pH of sal iva and/or urine about 0.2 to about 3.2 units on the pH scale, about 0.4 to about 2 units on the pi I scale, about 0.5 to about 1 u nit or more on the pi I scale.
  • Therapeutic effectiveness may also be determ ined using a Lactic acid meter.
  • physiological pH levels increase indicating an increase in ac id in the body.
  • the effect of alkaline water on lowering elevated physiological pi 1 can be determ ined using a lactic ac id meter. Measurements may be taken before, during, and after intense activity.
  • An effective amount of an A lkal ine water composition would maintain normal or decrease elevated levels of physiological pH during exercise. I n some embodiments, alkal ine water consumed during exercise wi ll decrease the drop in physiological pH. In other embodiments, alkaline water consumed during exercise wil l prevent a drop in physiological pH.
  • alkal ine water consumed after exercise will increase the rate at which physiological pH returns to basel ine levels.
  • the consumption of Alkaline water as described herei i during exercise wi ll increase an individual ' s maximal lactate steady stale al low ing them to exercise longer and harder than had previously been possible.
  • the normal blood lactate concentration is 1 -0.5 mmol/L. Individuals in various disease states may have lactate concentrations of less than 2 mmol/L.
  • Hyperlactem ia is defined as a m ild-to-moderate persistent increasing blood lactate concentration (2-5mmol/L) w ithout metabolic acidosis, whereas lactic acidosis is characterized by persistently increased blood lactate levels (usual ly >4-5mmol/L) in association with metabolic acidosis.
  • the Lactic threshold at which point exercise becomes more di fficult is between 2 to 4 mmol/L. Consumption of an effective amount of an Alkaline water composition as described herein wil l delay an increase in lactic acid levels during exercise and/or increase the rate at wh ich lactic acid levels return to normal levels after exercise.
  • Consumption of an effective amount of Alkal ine water as described herein wil l delay an increase in lactic acid levels during exercise by 5%, 1 0%, 20%, 30%, 50% or greater reduction, up to a 75-90%o, or 95% or greater. Furthermore, consumption of an effective amount of Alkaline water as described herein wil l decrease elevated lactic acid levels by 5%, 1 0%, 20%, 30%, 50% or greater reduction, up to a 75- 90%, or 95%) or greater, reduction regardless of the cause of the elevation, whether exercise or illness.
  • Therapeutic effectiveness may also be determ ined with a uric acid meter.
  • Normal uric acid is between 3.5mg/dL to 7.2mg/dL with 20mg/dL being a major gout attack. Elevated levels of uric acid may be due to acidosis. Consumption of an effective amount of Alkaline water as described herein will decrease uric ac id levels by 5%, 1 0%, 20%, 30%, 50% or greater reduction, up to a 75-90%. or 95% or greater.
  • the rate of Cytochrome C reduction can be measured using lum inol induced chemi lum inescence for quanti fying the results.
  • Therapeutically effective free radical reducing or antioxidant amounts of the solution of the present inventi on w i l l decrease the rate of cytochrome C reduction by 2-50%, 1 0-40%, 1 5-30%, 20- 25% or more, up to a 75-90%, or 95% or greater, reduction.
  • test subjects wi l l exhibit a 5%, 1 0%. 20%, 30%, 50% or greater reduction, up to a 75-90%, or 95% or greater, reduction, in one or more symptoms associated with ac idosis as compared to placebo-treated or ether suitable control subjects.
  • Test subjects may also exhibit a 1 0%, 20%. 30%, 50% or greater reduction, up to a 75-90%, or 95%o or greater, reduction, in the sy mptoms of one or more conditions associated with acidosis.
  • compositions of the present invention may be administered by any means that achieves the intended therapeutic or prophylactic purpose.
  • Suitable routes of adm in istration for alkalizing and antioxidant compositions of the invention comprising OIT solutions include, but are not lim ited to, oral, buccal, nasal, aerosol, mucosal, injectable, slow release, controlled release, iontophoresis, sonophoresis. and other conventional delivery routes, devices and methods.
  • combinatorial formulations and coordinate adm inistration methods employ an effective amount of OI compositions, and one or more additional active agent(s) that is/are combinatorially formulated or coordinately adm inistered with the OH " solution— yielding an effective formulation or method to modulate, alleviate, treat or prevent acidosis or excessive free radicals in a mammal ian subject.
  • exemplary combinatorial formulations and coordinate treatment methods in this context employ a base solution in combination with one or more add itional or adj unctive agent.
  • Such secondary or additional agents for use with in the formulat ions and methods of the present invention include, but are not l imited to, alkal inity increasing agents, adaptogens, am ino acids and am ino acid derivatives, anti-inflammatory agents, anti-nausea agents, analgesics, antioxidants, aphrodisiacs, detoxifying agents, dietary supplements, herbal supplements, calm ing agents, herbs and pl ant extracts, flavorings, essential nutrients, coenzymes, electrolytes, energy boosters, essential trace elements, flavonoids, hormones, immune boosters,
  • the secondary agent may be provided in any of a variety of forms, inc luding any polymorphs, enantiomers, pharmaceutical ly acceptable salts, solvates, hydrates, or com binations thereof.
  • Such combinations of an 01 f composition and secondary agent may be adm in istered either combinatorial ly or coordinately as disclosed herein to effectively optim ize health and performance; prevent il lness; decrease recovery times from exertion, i llness, and inj ury: inc rease energy levels: improve exercise performance; improve hydration; prevent muscle damage a fter exercise; and increase stam ina during exercise.
  • a lkal inity increasi ng agents for use within the formulations and methods of the present invention include, but are not l imited to sodium bicarbonate; a carbonate, a phosphate, or a hydroxide of sodium or potassium; magnesium carbonate;
  • magnesium hydroxide ammonium carbonate; ammonium bicarbonate;
  • Adaptogen agents for use within the formulations and methods herein include, but are not limited to, ashwagandha, eleutherococcus senticosus, reishi, astragalus, licorice root, panax quinquefolius, panax ginseng and schisandra berries.
  • Antioxidants included in the formulations provided herein may be in the form of nutritional supplements such as. but not limited to, vitamin A; vitamin C; vitamin
  • melatonin or coenzyme Q10 melatonin or coenzyme Q10; xanthine oxidase inhibitors, including, but not limited to, allopurinol and folic acid; NADPH oxidase inhibitors, including, but not limited to, adenosine; calcium channel blockers; superoxide dismutases;
  • catalases include, but not limited to deferoxamine, apotransferin and ceruloplasmin; beta carotene; ascorbates;
  • benzaldehyde derivatives such as those described in U.S. Patent Application No. 12/418,342, incorporated by reference herein in its entirety.
  • antioxidants may be present in plant extracts which may also be combined w ith the alkaline water.
  • Plant extracts may come from plant sources such as, but not limited to, apricot, acai fruit, acerola, apple, blueberry, blackberry, black currant, carrots, cherry, chokeberry, cranberry, elderberry, green tea, go j i berry, grape seed, mangosteen, maqui berry, milk thistle, pomegranate seed, prune, raspberry, red grape, rooibos, rosehips, strawberry, seabuckthorn, white grape, whole grape, yumberry and acerola fruit.
  • Vitamin, mineral and nutritional supplements for use herein may be in a variety of forms including, but not limited to, vitamin B complex, folic acid, niacin, niacinamide, pantothenic acid, pyridoxine I IC1, vitamin B2. folate, biotin, vitamin C, vitamin D, vitamin D3, vitamin E, vitamin , cyanocobalamin.
  • Amino acids, amino acid precursors and derivatives as used within the formulations herein may be branched or straight chain amino acids.
  • Exemplary amino acids, precursors and derivatives which may be used in the formulations and methods described herein include, but are not l imited to, 5-HTP, argi n ine, beta alanine, carnitine fumarate, citrul l ine malate, glutam ine peptide, glycine, 1- alanine.
  • E lectrolytes used with the formu lations herein include, but are not lim ited to, sodium chloride, sodium acetate, acidic sodium citrate, acidic sodi um phosph ate, sodium chloride, sodium bicarbonate, sodium bromide, sodium citrate, sodium lactate, sodium molybdate, sodium phosphate, anhydrous sodium su lphate, sodium sulphate, sodium tartrate, sodium benzoate, sodium selenite, and othe r sodium salts and mixtures thereof; potassium chloride, potassium acetate, potassium bicarbonate, potassium bromide, potassium citrate, potassium- D- gl uconate, monobasic potassium phosphate, potassium tartrate, potassium sorbate, potassium iodide, and other potassium salts and m ixtures thereof; magnesium carbonate, magnesium citrate, magnesium oxide, magnesium phosphate, as wel l as other magnesium salts and m ixtures thereof; calcium ch loride, calcium carbonate, calcium
  • Such electrol ytes may be included in the formulations described herein in proportions and amounts su itable to replenish salts lost during exercise or illness or otherwi se depleted.
  • Anti-inflammatory agents for use within the formulations and methods herei n include, but are not l imited to, extracts from plants such as maqui berry, m i lk th istle, skul l cap, red raspberry, red sour cherry, green tea and hops.
  • anti-nausea agents including, but not limited to, extracts from pepperm int, ginger and chamomile.
  • compositions and methods described herein inc ludes analgesic agents such as, but not l im ited to, white w i llow bark.
  • compositions and methods described herein may additionally include herbal supplements and extracts with beneficial properties including, but not lim ited to, passion flower, horny goat weed, skullcap, m i lk thistle, Echinacea, dandel ion leaf, St. John's wort, green tea, black tea, chamomi le or peppermint, or an extract thereof.
  • the formulations and methods described herein may further include plants with beneficial properties including, but not lim ited to, guarana seeds, acerola berries, coconut water, yerba mate, acai berry, ginseng root, panax ginseng root, ginkgo bi loba, white wi l low bark, acacia, ashwagandha, chokeberry, elderberry, cranberry, maqu i berry, blueberry, pomegranate, rooibos, goj i berry, elder berry , valerian, seabuckthorn, yumberry, blackberry, astragalus, damiana, and ginger.
  • beneficial properties including, but not lim ited to, guarana seeds, acerola berries, coconut water, yerba mate, acai berry, ginseng root, panax ginseng root, ginkgo bi loba, white wi l low bark, acacia, ashwag
  • Energy boosters that may increase performance and are contemplated for use with in the methods and formulations described herein include, but are not l i m ited to, creatine ethyl ester, creatine monohydrate, magnesium creatine chelate, creatine hydrochloride, creatine nitrate, creatine monohydrate and royal jel ly .
  • Usefu l flavonoids within the compositions and methods of the present invention are present in chamom i le extract, cocoa powder, red grape, black tea, and white tea, ginkgo bi loba, berries, parsley, and green tea some or all of wh ich may be included in the compositions and methods described herein.
  • Usefu l sedatives for use within the compositions and methods described herein include, but are not l im ited to, lavender, lemon balm, lemongrass, l inden, oatstraw, St. John " s wart, valerian root, kava kava, hops and passion flower.
  • Additional agents which may be included in the formu lations and methods described herein are immune boosters including, but not lim ited to, Echinacea and astragalus root.
  • flavoring agents for use with the compositions and methods described herein include, but are not lim ited to fruit juice, vegetable j uice, milk solids, fruit flavors, herbal flavor and m ixtures thereof.
  • the fruit j uice can be any citrus j uice, non- citrus j uice, or mixture thereof, which is known for use in di lute j uice beverages.
  • the j uice can be derived from, but not l im ited to, apple, cranberry, pear, peach, plum, apricot, nectarine, grape, guava, cherry, currant, raspberry, gooseberry, elderberry, blackberry, blueberry, strawberry, lemon, lime, mandarin, orange, tomato, lettuce, dandelion, rhubarb, pineapple, coconut, pomegranate, kiwi, mango, papaya, banana, watermelon, passion fruit, tangerine, and cantaloupe
  • the vegetable j uice can be any vegetable j uice generally consumed includ ing but not l imited to, celery, spinach, cabbage, watercress, carrot, beet, spiru lina, sweet potato, kale, romaine, collard greens, endive, escarole. bok choy, fennel, pars ley, wheat grass, or cucumber.
  • Formulations and methods herein may additionally include a protein source.
  • Protein sources include, but are not lim ited to, mi lk solids, calcium caseinatc, whey protein concentrate, whey protein isolate, whey protein hydrolysate, soy protein, casein hydrolysate, rice protein, wheat protein, corn protein, partial l y hydrolyzed whey protein, or ultra-filtered whey protein.
  • f ormulations and methods herein may further incl ude one or more sweeteners or other carbohydrate source.
  • Such sweeteners include, but arc not l im ited to, acesul fame potassium, aspartame, cane sugar, corn syrup, crystal l ine fructose, dextrose, D-ribose, fructose, glucose, glucose-fructose syrup, high fructose corn syrup, h igh fructose liquid sugar, honey, maltodextrin.
  • further additional or adj unctive therapeutic agents may include but are not l imited to. probenecid, al lopurinol, nonsteroidal anti-inflammatory drugs (NSA I Ds).
  • colchic ine corticosteroids, uricosuric agents, xanth ine oxidase inhibitors, losartan. fenofibrate, urate oxidase, Y-700, COX-2 inh ibitors, analgesics, corticostero ids, disease-modi fying anti-rheumatic drugs, antibiotics, vasodepressors, sul fasa lazine. radiation therapy, chemotherapy, duloxetin, m i lnacipran,gabapentin, pregabai in, and benzaldehyde derivatives such as those described in U .S. Patent Application No. 12/4 1 8,342, incorporated herein by reference in its entirety.
  • the alkal inity increasing agent may be adm inistered i n conjunction with an additional therapeutic agent to faci litate consumption of "he additional therapeutic agent.
  • some therapeutic agents may be extremely acidic. Such agents may be adm inistered in conj unction with the alkal inity increasing agent to neutral ize the acidity and increase the forms of adm in istration that would be acceptable.
  • the alkal in ity increasing agent may be used to temporari ly neutral ize stomach acid or other acid cond itions so that therapeutic agents wh ich are destroyed by ac id such as, but not l imited to, nutritional supplements or other organics such as vitamins, includi ng v itam in B 1 2, can be ingested.
  • the invention provides combinatorial alkal izing or antioxidant formulations comprising a base solution made from calc ium hydroxide and/or calcium oxide and one or more adj unctive agent(s) hav ing alkal izing or antioxidant activity, or both, or additional adjunctive agents w h ich may have neither alkal izing nor antioxidant activity but which are usefu l in t he treatment of underlying conditions or prophylactical ly.
  • the OH " solution and the adj unctive agent(s) having alkal izing and/or antioxidant activity, or non-alkal izing/antioxidant agents w i l l be present in a combined formulation in effective amounts, alone or in combination.
  • a base sol ution and a non-calcium hydroxide based a lkal izing and/or antioxidant agent wi l l each be present in an alkalizing and/or antioxidant amount (i.e., in singular dosage which wi l l alone elicit a detectable alkal izing or free radical reduced response in the subject).
  • the combinatorial formulation may comprise one or both of the OH " solution and a non-calcium hydroxide based alkal izing and/or antioxidant agent or other adj unctive agent in sub-therapeutic singular dosage amount(s), wherein the combinatorial formulation comprising both agents features a combined dosage of both agents that is collectively effective.
  • Effectiveness may elicit an alkal izing or free rad ical reducing response or other increased therapeutic response.
  • one or both of the OH " solution and a non-calcium hydroxide based alkalizing and/or antioxidant agents may be present in the formulation, or administered in a coordinate administration protocol, at a sub-therapeutic dose, but collectively in the formulation or method they elicit a detectable alkalizing and/or antioxidant response in the subject.
  • an OH " mixture is administered, simultaneously or sequentially, in a coordinate treatment protocol with one or more of the secondary or adjunctive therapeutic agents contemplated herein.
  • the coordinate administration may be done simultaneously or sequentially in either order, and there may be a time period while only one or both (or all) active agents, individually and/or collectively, exert their biological activities.
  • a distinguishing aspect of all such coordinate treatment methods is that the Ol ⁇ solution exerts at least some detectable alkalizing or antioxidant activity, and/or elicits a favorable clinical response, which may or may not be in conjunction with a secondary clinical response provided by the secondary therapeutic agent.
  • the coordinate administration of a base solution with a secondary agent as contemplated herein will yield an enhanced therapeutic response beyond the therapeutic response elicited by either or both the Ol I " solution and/or secondary therapeutic agent alone.
  • compositions of the invention comprising an effective amount of a base solution of the present invention vviil be routinely adjusted on an individual basis, depending on such factors as weight, age, gender, and condition of the individual, the severity of the acidosis, ROS levels including free radical production or related symptoms, whether the administration is prophylactic or therapeutic, and on the basis of other factors known to effect drug delivery, absorption, pharmacokinetics, including, but not limited to, half-life, and efficacy.
  • Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. Such animal models and systems are well known in the art.
  • the precise dose to be employed will also depend on the route of administration, the seriousness of the disease or disorder, and body size, and should be decided according to the judgment of the practitioner and each patient's circumstances. I lowever, suitable dosage ranges for oral administration are generally about 5 ounces (0.147 L) to about 135.256 ounces (4 L) of the diluted OH solution (having a pH between 7.5 and 9.5) per day.
  • the oral dose is about 5 ounces (0.147 mL) to about 100 ounces (2.9L), about 5 ounces (0.147L) to about 90 ounces (2.6 L) of OH " solution per day, more preferably about 8 ounces (236 mL) to about 80 ounces (2.36 L) of OH " solution per day. more preferably about 24 (0.7L) to about 32 ounces (.94L) per day, more preferably about 32 ounces (.94L) to about 48 ounces ( 1 .4L) per day. more preferably about 35 ounces ( 1 .035 L) to about 80 (2.361.) ounces per day.
  • the 01 solution is adm inistered over the course of a day, for example the dosage is taken over eight hours, ten hours, 5 twelve hours or 24 hours.
  • the dose may be cal ibrated based on body size, with effective doses comprising between about 0.0 1 to about 5 oz/pound, 0.3 to about 5 oz/pound, about 0.3 to about 3 oz/pound, about 0.3 to about 1 oz/pound, about 0.35 oz/pound.
  • an individual weigh ing 2251bs would be given a starting dose of about 80 ounces (2.36L) of di luted OHI O solution, as described in Example X; an individual weigh ing 1 80 pounds wou ld receive a starting dose of 64 oz ( 1 .9L) of the solution of Example X per day.
  • An i ndividual weigh ing 1 35 pounds would receive a starti ng dose of 48 oz ( 1 .4L) of the solution of Example X per day.
  • An individual weigh ing 90 pounds would be given a starting dose of 32 oz ( .94L) of the solution of Example X per day.
  • fractions of the dosage are admini stered at particular time points, for example every hour, every two hours, every three hours, every four 0 hours, every eight hours, every twelve hours, or any other fraction of time, as tolerated by the patient.
  • one ounce of anti-oxidant material could be m ixed in 1 l iter of water.
  • a maintenance dose may be 5 taken indefinitely.
  • a maintenance dose may be 1 ⁇ 2 of the therapeutic level, 1 /3 of the therapeutic level, 1 ⁇ 4 of the therapeutic level, or any other reduced dosage as determined by the j udgment of the practitioner and the patient ' s circumstances.
  • the formu lations may be presented in unit-dose or multi-dose containers.
  • Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as described herein above, or an appropriate fraction thereof, of the active ingredient(s).
  • eight ounces of the prepared formulation i s administered every four hours.
  • eight ounces of the prepared formulation is administered every three hours.
  • 0.5L is adm inistered every eight hours.
  • eight ounces of the prepared formulation is adm inistered every two hours or fraction thereof.
  • unit dose formulations are in 0.5 liters, or a m u lt iple thereof.
  • Dosage forms of the OH " solution of the present invention include excipicnts recognized in the art of compounding as being suitable for the preparation o f dosage units as discussed above. Such excipicnts incl ude, without intended l im itation, binders, ti l lers, lubricants, emulsitiers, suspend ing agents, sweeteners, flavorings, preservatives, buffers, and other conventional excipicnts and add itives.
  • compositions of the invention for altering physiological pi 1 can thus inc lude any one or combination of the following: a pharmaceutically acceptable carrier or excipient; other med icinal agent(s); pharmaceutical agent(s); adj uvants; buffers; preservatives; di luents; and various other pharmaceutical add itives and agents know n to those skilled in the art.
  • additional formulation additives and agents w i l l often be biological ly inactive and can be admin istered to patients without causing deleterious side effects or interactions with the active agent.
  • Additional OH " solutions of the invention can be prepared and adm inistered in any o f a variety of inhalation or nasal del ivery forms known in the art.
  • Devices capable of depositing aerosol ized OH " formulations in the sinus cavity or pu lmonary alveol i of a patient include metered dose inhalers, nebul izers, sprayers, and the l ike. Methods and compositions suitable for pulmonary del ivery of drugs for system ic effect are wel l known in the art. Suitable formulations, wherein the carrier is a l iquid, for adm inistration, as for example, a nasal spray or as nasal drops, may include aqueous or oi ly solutions of calcium hydroxide and any additional active or inactive ingredient(s).
  • n istration i nc lud ing aqueous and non-aqueous steri le injection solutions which may optionally contain antioxidants, buffers, bacteriostats and/or solutes w hich render the formulation isotonic with the blood of the mammal ian subject; and aqueous and non-aqueous steri le suspensions wh ich may include suspend ing agents and/or thickening agents.
  • the product may be manufac tured and sold as a ready-to-drink beverage for immediate consumption by a mammal ian subject.
  • the compositions described herein may be preferred in concentrat4e or powder form to be reconstituted for use by a mammalian subject by the addition of water. Such reconstitution is made with the requisite amounts of water to ensure that the beverage to be consumed contains the active components in the proportions previously noted.
  • liquid formulations as described herein may be sold as part of a kit includ ing a lactic acid meter, uric acid meter and/or pH test strips.
  • kits of the present invention comprise one or more compositions of the present invention together with the lactic acid meter, uric acid meter and/or pH test strips, information wh ich informs a user of the kit, by words, pictures, and / or the like, that use of the kit wil l provide one or more general health and / or general physiological benefits including, but not l im ited to. alkal ine increasing, health and performance optim izing, il lness preventing, energy level increasing, hydration increasing, recovery time decreasing, muscle protecting and stam ina increasing benefits and which informs the user of the method of monitori ng their acidosis levels.
  • the kit may comprise 7 bottles of .5 L of di luted alkal ine water at a pH of 7.5.
  • the k it may comprise 7 bottles of concentrated alkal ine water in 30mL bottles at a pi 1 of 12.5.
  • the invention disclosed herein will also be understood to encompass methods and compositions comprising a base solution using in vivo metabolic products of the said compounds (either generated in vivo after administration of the subject precursor compound, or directly administered in the form of the metabol ic product itself). Such products may result, for example, from the oxidation, reduction, hydrolysis, am idation, esterification and the l ike of the admin istered compound, primari ly due to enzymatic processes. Accordingly, the invention includes methods and compositions of the invention employing compounds produced by a process comprising contacting a base solution of the present invention with a mammal ian subject for a period of time sufficient to yield a metabolic produc t thereof.
  • the present invention relates to the creation of a strong base solution for use as an antioxidant and/or alkal in ity increasing agent.
  • OzoTech OZ2PCS ozone generator (OzoTech, I nc., Y reka, CA) unti l the pH of the solution is above 7.0. The di luted sul furic acid is then added to the fi ltered
  • example I is chi lled to below 36° F. for up to four hours, but not al lowed to freeze completely.
  • the partial ly frozen material is then filtered using a
  • Example I I I The solution of Example I I I was administered at the rate of 8 ounces every four hours until 24 to 32 ounces of the solution was consumed. Consumption of t his amount increases physiological pH to normal levels and decreases rates of infection.
  • Example V The solution of Example I I I was administered at the rate of 8 ounces every four hours until 24 to 32 ounces of the solution was consumed. Consumption of t his amount increases physiological pH to normal levels and decreases rates of infection.
  • COM- 100 Waterproof EC / TDS / Temp Combo Meter (HM Digital, Inc., Culver
  • the solution is filtered with a non-charcoal live micron filter and then decanted into 16.9 oz (.5L) containers for consumption.
  • each subject is then given 2L of Alkaline water in 0.5L doses taken four times a day as prepared i;i Example X daily for two weeks. After two weeks, the subjects are retested and the average heart rate (estimated heart rate at subject ' s lactate threshold) is compared.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux procédés de fabrication d'une solution de base non-corrosive destinée à être utilisée comme agent augmentant l'alcalinité et/ou un antioxydant. Les compositions et les procédés sont utiles pour optimiser la santé et une performance : prévenir une maladie; réduire des temps de récupération d'effort, de maladie et de lésion; accroître des niveaux d'énergie; améliorer une performance d'exercice; améliorer une hydratation; prévenir une lésion musculaire après un exercice; et accroître une endurance pendant un exercice. La présente invention concerne en outre de nouvelles compositions et de nouveaux procédés qui peuvent être utilisés pour atténuer des troubles associés à une production d'acidose ou de radical libre excessive ou de dérivé réactif de l'oxygène, ou compliqués par celle-ci.
PCT/US2014/022204 2013-03-08 2014-03-09 Boisson d'optimisation physique Ceased WO2014138723A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/881,880 US20200281968A1 (en) 2013-03-08 2020-05-22 Physical optimization beverage

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361774626P 2013-03-08 2013-03-08
US201361774622P 2013-03-08 2013-03-08
US61/774,622 2013-03-08
US61/774,626 2013-03-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/201,865 Continuation US20140255371A1 (en) 2013-03-08 2014-03-09 Physical Optimization Beverage

Publications (2)

Publication Number Publication Date
WO2014138723A2 true WO2014138723A2 (fr) 2014-09-12
WO2014138723A3 WO2014138723A3 (fr) 2014-11-06

Family

ID=51492038

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/022204 Ceased WO2014138723A2 (fr) 2013-03-08 2014-03-09 Boisson d'optimisation physique
PCT/US2014/022203 Ceased WO2014138722A1 (fr) 2013-03-08 2014-03-09 Procédé de préparation d'une solution de base non corrosive et procédés d'utilisation associés

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2014/022203 Ceased WO2014138722A1 (fr) 2013-03-08 2014-03-09 Procédé de préparation d'une solution de base non corrosive et procédés d'utilisation associés

Country Status (1)

Country Link
WO (2) WO2014138723A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108408866A (zh) * 2017-02-09 2018-08-17 朱洪立 三清负离子水
CN118766813B (zh) * 2024-07-25 2025-04-08 诺德溯源(广州)生物科技有限公司 一种高活性成分保留的提取工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU534068B2 (en) * 1978-10-13 1984-01-05 Century Science Corporation Treatment and detection of beta-glucuronidase activity conditions with glucuronides
US4830862A (en) * 1987-07-31 1989-05-16 The Procter & Gamble Company Calcium-supplemented beverages and beverage concentrates containing low levels of sulfate
WO2005074724A1 (fr) * 2004-02-04 2005-08-18 Kim, Won-Jik Boisson a base d'ions de calcium a partir d'une solution aqueuse de calcium permettant l'absorption de calcium a une concentration elevee et son procede de fabrication
GB0619786D0 (en) * 2006-10-06 2006-11-15 Inst Of Technology Sligo An antimicrobial and immunostimulatory system
DE102007003463B4 (de) * 2007-01-24 2012-12-13 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Rohsaftalkalisierung
US8273384B2 (en) * 2007-07-02 2012-09-25 Stephen Ray Wurzberger Process for the preparation of a non-corrosive base solution and methods of using same
CA2717088A1 (fr) * 2007-09-13 2009-03-26 Rheinkalk Gmbh Procede d'augmentation de ph d'eaux acides
DE102007049612A1 (de) * 2007-10-17 2009-06-10 Evonik Goldschmidt Gmbh Bioaktive Zusammensetzung für kosmetische Anwendungen
EP2219600A4 (fr) * 2007-11-19 2012-09-12 Stiefel Laboratories Compositions cosmétiques topiques d'éclaircissement de la peau et leurs procédés d'utilisation
WO2010039205A2 (fr) * 2008-09-30 2010-04-08 Paul Michael Pedersen Appareil destiné à alcaliniser l’eau
CN104983740A (zh) * 2010-05-07 2015-10-21 利发利希奥公司 用于增强生理性能和恢复时间的组合物和方法

Also Published As

Publication number Publication date
WO2014138723A3 (fr) 2014-11-06
WO2014138722A1 (fr) 2014-09-12

Similar Documents

Publication Publication Date Title
US20200281968A1 (en) Physical optimization beverage
ES2286238T3 (es) Composicion para rehidratacion.
US20200206168A1 (en) Compositions comprising beta-hydroxybutyric acid and salt, and methods of using the same
CN108024981B (zh) 一种治疗肾病患者的羧酸组合物
ES2849552T3 (es) Procedimiento para suministrar una bebida a base de agua, enriquecida con magnesio y / o calcio
JPS5838421B2 (ja) 分岐鎖状ケト酸のオルニチン及びアルギニン塩並びに肝臓及び腎臓障害の治療への使用
Fürst Amino acid metabolism in uremia.
EA025137B1 (ru) Раствор для диализа, включающий одно или более соединений креатина и способ его получения
US20050260277A1 (en) Method and formula for anti-tumor and anti-matastatic effect
WO1987003806A1 (fr) Therapie de nutrition parenterale avec acides amines
HU226984B1 (en) Medical and food products for treating diabetes mellitus and process for producing thereof
CN103327950B (zh) 中性环境中稳定的高浓度磷酸钙水溶液的制备方法
CA2409834A1 (fr) Boisson energetique et methode de preparation
KR20100015922A (ko) 암 환자용 수액 제제
WO2014138723A2 (fr) Boisson d'optimisation physique
US20140147519A1 (en) Migraine Treatment
WO2001015745A9 (fr) Procede et formule destines a la remission des tumeurs et a la suppression du cancer
WO2015107241A1 (fr) Formulation de sels de réhydratation liposomale
WO2007108712A1 (fr) Kit et procédé servant à traiter ou à prévenir une anémie provoquée par une carence en fer
US20140255465A1 (en) Process For The Preparation Of A Non-Corrosive Base Solution And Methods Of Using Same
JP2007197363A (ja) 栄養補助剤
KR20120119686A (ko) Ｌ-아르기닌, 비타민ｃ, 비타민 ｂ군, 비타민ａ, 비타민ｅ 및 요오드화칼륨을 주성분으로 함유하는 기능성 음료조성물
CN112438949A (zh) 一种含钙补充剂的盐酸托莫西汀口服液及其制备方法
RU2527042C1 (ru) Биологически активная добавка к пище для профилактики заболеваний остеопорозом
JPH07267855A (ja) グルタミン産生剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14759835

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 21-12-2015)

122 Ep: pct application non-entry in european phase

Ref document number: 14759835

Country of ref document: EP

Kind code of ref document: A2